Advertisement

Topics

IMAXIO SA Company Profile

01:19 EST 18th November 2017 | BioPortfolio

Imaxio develops therapeutic and theranostic products that address currently unmet medical needs, particularly in the field of infectious diseases and oncology. Our integrated infrastructure enables in-house development, production and marketing of vaccines.

Our development is based on a core growth served by our product and services to the industry. We also strive to strengthen our company through active Mergers and Acquisitions activities in order to sustain internal R&D programs and acquire synergistic products or technologies.

Imaxio originally started in September 2000 as a spin-off company - called Avidis - from the Medical Research Council and Cambridge University (UK). The company developed a recombinant protein refolding technology and OverExpress® competent cells for the expression of recombinant proteins. More applications of this technology were developed during the next four years, before reengineering of the company in 2004 with the purpose to focus on vaccines.

In 2006, Avidis and Diagnogene joined forces to become Imaxio. Later in the year, Imaxio further strengthened its presence in the protein engineering industry through the acquisition of the peptide aptamer technology assets from a French company called Aptanomics.

In order to sustain its strategy based on the combination of commercial and R&D activities, Imaxio has developed successful drug discovery and genomic services to the industry.

In early 2009, Imaxio acquired Axcell Biotechnologies, a French biopharmaceutical company.

Location

Biopole Clermont-Limagne
Saint-Beauzire
63360
France

Contact

Phone: 33(0)473 64 43 90
Fax: 33(0)473 64 43 93
Email: contact@imaxio.com


News Articles [1 Associated News Articles listed on BioPortfolio]

Imaxio SA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 22082017] Prices from USD $250

SummaryImaxio SA Imaxio is a biotechnology company that owns a pipeline of vaccines composed marketed, clinicalstage and preclinicalstage products. The company provides vaccine against human leptospir...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

IMAXIO SA

Imaxio develops therapeutic and theranostic products that address currently unmet medical needs, particularly in the field of infectious diseases and oncology. Our integrated infrastructure enables ...

More Information about "IMAXIO SA" on BioPortfolio

We have published hundreds of IMAXIO SA news stories on BioPortfolio along with dozens of IMAXIO SA Clinical Trials and PubMed Articles about IMAXIO SA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of IMAXIO SA Companies in our database. You can also find out about relevant IMAXIO SA Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record